Neurocrine Biosciences, Inc. (NBIX) Reports In-Line Q4 EPS of $0.02, Offers Poor FY12 Guidance
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) reported Q4 EPS of $0.02, in-line with the analyst estimate of $0.02. Revenue for the quarter came in at $11.1 million versus the consensus estimate of $12.08 million.
Neurocrine Biosciences, Inc. sees FY2012 EPS of $-0.21-$-0.14, versus the consensus of $0.02. Neurocrine Biosciences, Inc. sees FY2012 revenue of $40-$45 million, versus the consensus of $51.72 million. The Company expects to have a net cash burn from operations of approximately $40 to $45 million in 2012.
For earnings history and earnings-related data on Neurocrine Biosciences, Inc. (NBIX) click here.
Neurocrine Biosciences, Inc. sees FY2012 EPS of $-0.21-$-0.14, versus the consensus of $0.02. Neurocrine Biosciences, Inc. sees FY2012 revenue of $40-$45 million, versus the consensus of $51.72 million. The Company expects to have a net cash burn from operations of approximately $40 to $45 million in 2012.
For earnings history and earnings-related data on Neurocrine Biosciences, Inc. (NBIX) click here.